AstraZeneca and the Bellvitge University Hospital have announced their plans to launch a pilot program for the Cordio Medical HearO app, which aims to provide widespread access to medical-grade technology for patients with congestive heart failure (CHF).

HearO is an AI voice biomarker solution that monitors patients’ unique speech patterns to detect warning signs of worsening or possible complications. The advanced algorithmic technology offers a cost-effective and easy-to-use tool that enables the early detection of CHF symptoms, allowing doctors to optimize patient-specific treatment plans.

The pilot program will assess the feasibility of using the app to monitor CHF patients in both hospital and at-home settings. It will also evaluate the app’s success rate in patient compliance and its ability to issue notices before heart failure events. The study will take place over a period of 6-9 months.

Previous studies conducted in Israel and the U.S. have tested and validated the technology behind HearO. These studies demonstrated an impressive 82% success rate in predicting heart decompensation events up to 22 days in advance.

AstraZeneca and Cordio are at the forefront of digital health, and this pilot program aims to familiarize cardiologists, nurses, and patients with the medical-grade digital system. They hope to set an example for other healthcare providers to efficiently implement the HearO app in different healthcare systems.

Article written by Sean Wooley



Medica Design